TGFB1 and prostate carcinoma: For instance, antibodies blocking integrins (e.g., 10D5 and 264RAD) efficiently impair the growth of primary and secondary tumors in models of breast and prostate cancers, though the effects exerted by these therapies could also be related to reduced TGF-β-mediated immunosuppression and angiogenesis (Moore et al., 2014; Dutta et al., 2015).